Approved comparison material connected to this topic.
11 total recordsSource comparisons are presented without a generated winner.
Sermorelin stimulates GH release through GHRH receptor activation on anterior pituitary somatotrophs. The same pathway your hypothalamus uses naturally. The dose-response relationship in younger populations di…
Starting Dose 200 mcg nightly 500 mcg nightly 750–1000 mcg nightly Younger populations require 60% lower starting doses due to intact GHRH receptor density and higher baseline somatotroph responsiveness Maximu…
Initial Dose 300mcg subcutaneously at bedtime 200–250mcg subcutaneously at bedtime for first 14 days Lower starting dose reduces GI side effects (nausea, cramping) and allows patients to acclimate to injection…
200–250mcg nightly Men with baseline IGF-1 >180 ng/mL, mild recovery deficits 15–25% from baseline 8–12 weeks to measurable body composition change Sleep quality improvement, minor body recomposition Effective…
Mechanism GHRH analogue. Stimulates endogenous pulsatile GH release GHRH analogue. Higher dose compensates for receptor density decline Exogenous recombinant human growth hormone. Bypasses pituitary Sermorelin…
Starting Dose 200mcg nightly, weeks 1-4 300mcg nightly, weeks 1-2 500mcg from week 1 Conservative allows receptor re-sensitization. Best for women with prior GH/peptide exposure or metabolic dysfunction Escala…
Starting Dose 100–150mcg nightly 200–250mcg nightly 150–200mcg nightly Postmenopausal women require 30–50% higher doses due to estrogen withdrawal reducing hepatic GH receptor density Target IGF-1 Range 180–25…
Before initiating any protocol, understanding how sermorelin addresses specific perimenopause symptoms at the mechanistic level clarifies realistic expectations and response timelines. Night sweats / hot flash…
Mechanism Telomerase gene activation (TERT) GHRH receptor agonism (pituitary GH release) Non-overlapping targets. No competitive inhibition Half-Life 2–4 hours (tissue retention ~72h) 8–12 minutes (cleared rap…
Conservative Initiation 200mcg nightly 5 nights/week 20–35ng/mL from baseline First-time peptide users, baseline IGF-1 >150ng/mL, or age >55 with unknown GH reserve Minimises side effects, allows receptor sens…
Tendon strain (acute) 300–500mcg SC near injury site, daily 200mcg SC before sleep, daily 4–6 weeks BPC-157: angiogenesis + collagen synthesis; Sermorelin: systemic IGF-1 elevation Inject BPC-157 within 2cm of…